Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Pernix Subsidiaries Receives Approval For VITUZ, Mefenamic Acid Capsules

RELATED NEWS
Trade PTX now with 

Hawthorn Pharmaceuticals, Inc., a subsidiary of Pernix Therapeutics Holdings, Inc. (PTX: Quote) Thursday said it has received approval from the U.S. Food and Drug Administration, or FDA, for VITUZ Oral Solution.

VITUZ solution is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older.

The company also said that its subsidiary, Cypress Pharmaceuticals, Inc., has been granted final approval by the FDA for Mefenamic Acid Capsules USP, 250 mg, a generic version of Ponstel Capsules, 250 mg, indicated for relief of mild-to-moderate pain in patients treated of primary dysmenorrhea.

"VITUZ broadens our cough and cold product line and is our first NDA approved by the FDA, since the acquisition of Hawthorn and Cypress, " said Cooper Collins, President, CEO.

Launch of the new treatment option for cough and cold symptoms is expected prior to the fall of 2012. Mefenamic Acid Capsules are expected to launch in the second quarter.

Click here to receive FREE breaking news email alerts for Pernix Therapeutics Holdings Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After trending higher over the past several sessions, stocks may give back some ground in early trading on Friday. The major index futures are currently pointing to a modestly lower open for the markets, with the Dow futures down by 19 points. UN human rights chief has called attention to "the international paralysis" on finding a solution to the conflict in Syria, which according to her empowered and emboldened the "killers, destroyers and torturers" in the country. UN High Commissioner for Human Rights Navi Pillay on Friday appealed to Governments to take serious measures to halt the fighting and deter the crimes, and above all "sto Fashion retailer Gap Inc. said Thursday after the markets closed that its second quarter profit rose 10% from last year, helped by higher sales and a gain from asset sale. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarter sales. Separately, Gap announced plans to enter India through franchise-operated Gap brand stores in 2015.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.